[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Advisory Board
Aims & Scope
Journal News
Articles archive::
All Issues
Current Issue
Articles in press
Browse by Authors
Browse by Keywords
For Authors::
Submission Instruction
For Reviewers::
Reviewers Section
Subscription::
Subscription Form
News& Events::
Journal News
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
Top 10 contents
Inform others
Ethics & Permissions::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 10, Issue 2 (Summer 2013) ::
Sci J Iran Blood Transfus Organ 2013, 10(2): 129-139 Back to browse issues page
Apoptotic effect of arsenic trioxide plus Azidothymidine on APL cell line (NB4) through P21 expression and cell cycle distribution changes
S. Hasani , F. Zaker , A. Zekri , A. Zaghal , K. Alimoghaddam , A. Ghavamzadeh , S.H. Ghaffari *
Keywords: Key words: Acute Promyelocytic Leukemia, arsenic trioxide, Azidothymidine, Apoptosis
Full-Text [PDF 523 kb]   (3525 Downloads)     |   Abstract (HTML)  (14439 Views)
Type of Study: Research | Subject: Hematology
Published: 2013/08/24
Full-Text:   (2394 Views)
References:
  1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111(5): 2505-15.
  2. Emadi A, Gore SD. Arsenic trioxide - An old drug rediscovered. Blood Rev 2010; 24(4-5): 191-9.
  3. Sanz MA, Fenaux P, Lo Coco F; European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90(9): 1231-5.
  4. Taylor BF, McNeely SC, Miller HL, Lehmann GM, McCabe MJ Jr, States JC. p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1. J Pharmacol Exp Ther 2006; 318(1): 142-51.
  5. Zheng Y, Shi Y, Tian C, Jiang C, Jin H, Chen J, et al. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic  trioxide. Oncogene 2004; 23(6): 1239-47.
  6. Li J, Chen P, Sinogeeva N, Gorospe M, Wersto RP, Chrest FJ, et al. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 2002; 277(51): 49504-10.
  7. Zhu J, Okumura H, Ohtake S, Nakamura  S,  Nakao  S. Arsenic  trioxide   induces   apoptosis   in    leukemia   /lymphoma cell lines via the CD95/CD95L system. Oncol Rep 2003; 10(3): 705-9.
  8. Pan XY, Chen GQ, Cai L, Buscemi S, Fu GH. Anion exchanger 2 mediates the action of arsenic trioxide. Br J Haematol 2006; 134(5): 491-9.
  9. Mathieu J, Besançon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Ann N Y Acad Sci 2006; 1090: 203-8.
  10. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell  apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88(3): 1052-61.
  11. Mandegary A, Hosseini R, Ghaffari SH, Alimoghaddam K, Rostami S, Ghavamzadeh A, et al. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. Ann Oncol 2010; 21(9): 1884-90.
  12. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 2001; 112(3):
783-6.
  1. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002; 8(2): 566-72.
  2. Diaz Z, Colombo M, Mann KK, Su H, Smith KN, Bohle DS, et al. Trolox selectively enhances arsenic-mediated oxidative  stress  and  apoptosis  in  APL  and
 
other malignant cell lines. Blood 2005; 105(3): 1237-45.
  1. Zhang Y, Cao EH, Liang XQ, Qin JF. Increasing sensitivity to arsenic trioxide-induced apoptosis by altered telomere state. Eur J Pharmacol 2003; 474(2-3): 141-7.
  2. Melana SM, Holland JF, Pogo BG. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythymidine. Clin Cancer Res 1998; 4(3): 693-6.
  3. Humer J, Ferko B, Waltenberger A, Rapberger R, Pehamberger H, Muster T. Azidothymidine inhibits melanoma cell growth in vitro and in vivo. Melanoma Res 2008; 18(5): 314-21.
  4. Fang JL, Beland FA. Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci 2009; 111(1): 120-30.
  5. Fang JL, McGarrity LJ, Beland FA. Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T 3cells. Mutagenesis 2009; 24(2): 133-41.
  6. Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, et al. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 1996; 14(3): 729-36.
  7. Morgan RJ, Jr., Newman EM, Sowers L, Scanlon K, Harrison J, Akman S, et al. Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemother Pharmacol 2003; 51(6): 459-64.
  8. Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey NL, Cabral L, et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 2005; 106(1): 235-40.
  9. Ji HJ RS, Jeung HC, Yang SH, An SW, Chung HC. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res Treat 2005; 93(3): 227-36.
  10. Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer 2009; 125(2): 264-75.
  11. Sun YQ, Guo TK, Xi YM, Chen C, Wang J, Wang ZR. Effects of AZT and RNA-protein complex (FA-2-b-beta) extracted from Liang Jin mushroom on apoptosis of gastric cancer cells. World J Gastroenterol 2007; 13(31): 4185-91.
  12. Chiu DT DP. The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy. Genetica  1995; 95(1-3): 103-9.
  13. Momeny M, Zakidizaji M, Ghasemi R, Dehpour AR, Rahimi-Balaei M, Abdolazimi Y, et al. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73  transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol 2010; 27(3): 833-42.
  14. Abbas T, Dutta A. p21  in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9(6): 400-14.
  15. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, et al. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003; 17(7): 1333-7.
  16. Olivero OA, Tejera AM, Fernandez JJ, Taylor BJ, Das S, Divi RL, et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 2005; 20(2): 139-46.
  17. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004 ; 23(16): 2825-37.
 
  1. Carney DA. Arsenic trioxide mechanisms of action-looking beyond acute promyelocytic leukemia. Leuk Lymphoma 2008; 49(10): 1846-51.
  2. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3(9): 1034-6.
  3. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996 ; 381(6584): 713-6.
  4. Bissonnette N, Hunting DJ. p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 1998; 16(26): 3461-9.
  5. Liu S BW, Liu M. Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003; 6(4): 183-95.

 
 
Original Article
 
 
 
 
Sci J Iran Blood Transfus Organ 2013; 10(2): 129-139
 
 
 
 
 
 


Apoptotic effect of arsenic trioxide plus Azidothymidine
 on APL cell line (NB4) through P21 expression
and cell cycle distribution changes
 
Hassani S.1, Zaker F.1, Zekri A.2, Zaghal A.3, Alimoghaddam A.3,
Ghavamzadeh A.3, Ghaffari S.H.3
 
 
1School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
2School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3Hematology, Oncology and Stem Cell Research Center of Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
 
Abstract
Background and Objectives
Arsenic trioxide (ATO) is an active drug in treatment of acute promyelocytic leukemia (APL), but has adverse effects on patients. In order to enhance antileukemic effectiveness and to reduce dosage of ATO, combinatorial effect of it with Azidothymidine (AZT) in apoptosis induction was evaluated on APL cell line (NB4).
 
Materials and Methods
The cells cultured and treated with 50 μM AZT and/or ATO for 48 hrs and then with apoptosis, cell cycle distribution, and P21 mRNA levels in comparison with untreated cells (control) were analyzed by flow cytometry and Real Time PCR, respectively.
 
Results
ATO led to induction of apoptosis (50.14% ± 7.12) in comparison with the control (3.9% ± 2.97) through the increment of the cell cycle arrest in G2/M. The apoptotic effect of ATO had been inhibited in cells treated with combination of AZT/ATO (24.35% ± 4.65). This inhibition was associated with the relative reduction of the cells in G2/M and relative increase of the cells in G1 phase. While ATO had suppressive effect on p21 gene expression (0.27±0.14), AZT (1.81 ± 0.21) and AZT/ATO (2.06 ± 0.32) induced it.
 
Conclusions 
AZT attenuates ATO-caused apoptosis possibly through the induction of p21 expression and subsequent relative evasion from G2/M arrest and accumulation of cells in G1 phase.
 
Key words: Acute Promyelocytic Leukemia, arsenic trioxide, Azidothymidine, Apoptosis
 
 
 
 
 
 
Received: 30 May 2012
Accepted:  7 Oct  2012
 
 
 

Correspondence: Ghaffari SH., PhD of Molecular Genetics. Associate Professor of Hematology, Oncology and Stem Cell Research Center, Tehran University of  Medical Sciences, Shariati Hospital, Kargar Street.
Postal code: 14111, Tehran, Iran. Tel: (+9821) 84902665; Fax: (+9821) 88004140
E-mail:
shghaffari@tums.ac.ir
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hasani S, Zaker F, Zekri A, Zaghal A, Alimoghaddam K, Ghavamzadeh A et al . Apoptotic effect of arsenic trioxide plus Azidothymidine on APL cell line (NB4) through P21 expression and cell cycle distribution changes . Sci J Iran Blood Transfus Organ 2013; 10 (2) :129-139
URL: http://bloodjournal.ir/article-1-769-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 2 (Summer 2013) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.06 seconds with 39 queries by YEKTAWEB 4682